<code id='4A41D37120'></code><style id='4A41D37120'></style>

<acronym id='4A41D37120'></acronym>

<center id='4A41D37120'><center id='4A41D37120'><tfoot id='4A41D37120'></tfoot></center><abbr id='4A41D37120'><dir id='4A41D37120'><tfoot id='4A41D37120'></tfoot><noframes id='4A41D37120'>

<optgroup id='4A41D37120'><strike id='4A41D37120'><sup id='4A41D37120'></sup></strike><code id='4A41D37120'></code></optgroup>

<b id='4A41D37120'><label id='4A41D37120'><select id='4A41D37120'><dt id='4A41D37120'><span id='4A41D37120'></span></dt></select></label></b><u id='4A41D37120'></u>

~~<i id='4A41D37120'><strike id='4A41D37120'><tt id='4A41D37120'><pre id='4A41D37120'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：fashion 2025-10-01 04:34:39 Page View：23

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

advertisement

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Crowdfunding for medical bills sidesteps core problem, author says
Next article： Peter Hotez and the public health issue of online harassment

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Deliver public health messages at the right time

Deliver public health messages at the right time

AdobeIwas31yearsoldwhenmymotherwasdyingofbreastcancer.Oneday,whilesittingwithherinthehospital,heronc

Drug repurposing or repositioning? The language matters

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

AltruBio raises $225 million to develop ulcerative colitis drug

Micrographofchronicactiveulcerativecolitisinabiopsyspecimen.WikimediaCommonsCheckpointinhibitors,dru

read more